ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval

Submitted by admin on September 3, 2024 - 11:19am

Source:

Fierce Biotech

News Tags:

ProKidney

cell therapy

chronic kidney disease

rilparencel

Headline:

ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval

snippet:

ProKidney has stopped one of a pair of phase 3 trials for its cell therapy for kidney disease after deciding it wasn’t essential for securing FDA approval.

The product, called rilparencel or REACT, is an autologous cell therapy creating by identifying progenitor cells in a patient’s biopsy.

Search form

You are here

ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval

ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval